ERNA

Eterna Therapeutics (ERNA)

Eterna Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ERNA

1 2 3 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/15	06 : 14	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/05/10	21 : 00	GlobeNewswire Inc.	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs i	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/05/08	22 : 31	GlobeNewswire Inc.	Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/05/07	21 : 00	GlobeNewswire Inc.	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/05/07	21 : 00	GlobeNewswire Inc.	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs i	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/02/20	22 : 30	GlobeNewswire Inc.	Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/02/17	07 : 30	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/02/16	21 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/31	21 : 05	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/25	06 : 15	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/23	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/20	06 : 16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/20	00 : 31	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/17	06 : 16	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/13	06 : 49	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/04	07 : 02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/04	07 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/04	07 : 01	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/04	06 : 15	GlobeNewswire Inc.	Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/12/23	02 : 05	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/12/21	06 : 20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/12/21	06 : 15	GlobeNewswire Inc.	Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/12/21	05 : 24	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/12/21	00 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/12/19	11 : 38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/12/15	08 : 56	GlobeNewswire Inc.	Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/12/15	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/11/17	06 : 16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/11/14	07 : 30	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/11/13	22 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ERNA	Eterna Therapeutics Inc